FGFR2 amplification is predictive of sensitivity to regorafenib in gastric and colorectal cancers in vitro

Although regorafenib has demonstrated survival benefits in patients with metastatic colorectal and gastrointestinal stromal tumors, no proven biomarker has been identified for predicting sensitivity to regorafenib. Here, we investigated preclinical activity of regorafenib in gastric and colorectal c...

Descripción completa

Detalles Bibliográficos
Autores principales: Cha, Yongjun, Kim, Hwang‐Phill, Lim, Yoojoo, Han, Sae‐Won, Song, Sang‐Hyun, Kim, Tae‐You
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6026866/
https://www.ncbi.nlm.nih.gov/pubmed/29573334
http://dx.doi.org/10.1002/1878-0261.12194

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6026866/
https://www.ncbi.nlm.nih.gov/pubmed/29573334
http://dx.doi.org/10.1002/1878-0261.12194

Ejemplares similares